Outsmarting Pathogens with Antibody Engineering

Overview

Journal Annu Rev Chem Biomol Eng

Publisher Annual Reviews

Specialties Biochemistry
Molecular Biology

Date 2023 Mar 14

PMID 36917814

Authors

Ahlam N Qerqez

Rui P Silva

Jennifer A Maynard

Affiliations

Soon will be listed here.

Abstract

There is growing interest in identifying antibodies that protect against infectious diseases, especially for high-risk individuals and pathogens for which no vaccine is yet available. However, pathogens that manifest as opportunistic or latent infections express complex arrays of virulence-associated proteins and are adept at avoiding immune responses. Some pathogens have developed strategies to selectively destroy antibodies, whereas others create decoy epitopes that trick the host immune system into generating antibodies that are at best nonprotective and at worst enhance pathogenesis. Antibody engineering strategies can thwart these efforts by accessing conserved neutralizing epitopes, generating Fc domains that resist capture or degradation and even accessing pathogens hidden inside cells. Design of pathogen-resistant antibodies can enhance protection and guide development of vaccine immunogens against these complex pathogens. Here, we discuss general strategies for design of antibodies resistant to specific pathogen defense mechanisms.

Citing Articles

Reprogramming human B cells with custom heavy-chain antibodies.

Rogers G, Huang C, Mathur A, Huang X, Chen H, Stanten K Nat Biomed Eng. 2024; 8(12):1700-1714.

PMID: 39039240 DOI: 10.1038/s41551-024-01240-4.

References

Chen X, Schneewind O, Missiakas D . Engineered human antibodies for the opsonization and killing of . Proc Natl Acad Sci U S A. 2022; 119(4). PMC: 8795526. DOI: 10.1073/pnas.2114478119. View

Xiang Y, Huang W, Liu H, Sang Z, Nambulli S, Tubiana J . Superimmunity by pan-sarbecovirus nanobodies. Cell Rep. 2022; 39(13):111004. PMC: 9174178. DOI: 10.1016/j.celrep.2022.111004. View

Xiang Y, Nambulli S, Xiao Z, Liu H, Sang Z, Duprex W . Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science. 2020; 370(6523):1479-1484. PMC: 7857400. DOI: 10.1126/science.abe4747. View

Huang J, Gingerich A, Royer F, Paschall A, Pena-Briseno A, Avci F . Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection. Infect Immun. 2021; 89(5. PMC: 8091081. DOI: 10.1128/IAI.00747-20. View

Kajihara K, Pantua H, Hernandez-Barry H, Hazen M, Deshmukh K, Chiang N . Potent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate. mBio. 2021; 12(3):e0020221. PMC: 8262897. DOI: 10.1128/mBio.00202-21. View

Bournazos S, Klein F, Pietzsch J, Seaman M, Nussenzweig M, Ravetch J . Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014; 158(6):1243-1253. PMC: 4167398. DOI: 10.1016/j.cell.2014.08.023. View

Shi M, Chen X, Sun Y, Kim H, Schneewind O, Missiakas D . A protein A based Staphylococcus aureus vaccine with improved safety. Vaccine. 2021; 39(29):3907-3915. PMC: 8259053. DOI: 10.1016/j.vaccine.2021.05.072. View

Granoff D, Giuntini S, Gowans F, Lujan E, Sharkey K, Beernink P . Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding. JCI Insight. 2016; 1(14):e88907. PMC: 5033880. DOI: 10.1172/jci.insight.88907. View

Starr T, Greaney A, Addetia A, Hannon W, Choudhary M, Dingens A . Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021; 371(6531):850-854. PMC: 7963219. DOI: 10.1126/science.abf9302. View

10.

Bai Y, Ye L, Tesar D, Song H, Zhao D, Bjorkman P . Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proc Natl Acad Sci U S A. 2011; 108(45):18406-11. PMC: 3215070. DOI: 10.1073/pnas.1115348108. View

11.

Gray M, Hewlett E . Cell cycle arrest induced by the bacterial adenylate cyclase toxins from Bacillus anthracis and Bordetella pertussis. Cell Microbiol. 2010; 13(1):123-34. PMC: 4137770. DOI: 10.1111/j.1462-5822.2010.01525.x. View

12.

Varshney A, Kuzmicheva G, Lin J, Sunley K, Bowling Jr R, Kwan T . A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018; 13(1):e0190537. PMC: 5783355. DOI: 10.1371/journal.pone.0190537. View

13.

DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, Minter R . Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med. 2012; 209(7):1273-87. PMC: 3405507. DOI: 10.1084/jem.20120033. View

14.

Brezski R, Vafa O, Petrone D, Tam S, Powers G, Ryan M . Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci U S A. 2009; 106(42):17864-9. PMC: 2758810. DOI: 10.1073/pnas.0904174106. View

15.

Frank I, Friedman H . A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J Virol. 1989; 63(11):4479-88. PMC: 251078. DOI: 10.1128/JVI.63.11.4479-4488.1989. View

16.

Setliff I, Shiakolas A, Pilewski K, Murji A, Mapengo R, Janowska K . High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell. 2019; 179(7):1636-1646.e15. PMC: 7158953. DOI: 10.1016/j.cell.2019.11.003. View

17.

Guthmiller J, Han J, Utset H, Li L, Lan L, Henry C . Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature. 2021; 602(7896):314-320. PMC: 8828479. DOI: 10.1038/s41586-021-04356-8. View

18.

Zhu Q, McLellan J, Kallewaard N, Ulbrandt N, Palaszynski S, Zhang J . A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017; 9(388). DOI: 10.1126/scitranslmed.aaj1928. View

19.

Francois B, Mercier E, Gonzalez C, Asehnoune K, Nseir S, Fiancette M . Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Med. 2018; 44(11):1787-1796. DOI: 10.1007/s00134-018-5229-2. View

20.

Rouha H, Weber S, Janesch P, Maierhofer B, Gross K, Dolezilkova I . Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies. Virulence. 2017; 9(1):231-247. PMC: 5955178. DOI: 10.1080/21505594.2017.1391447. View